Infectious Diseases in Critical Care Medicine

44. World Health Organization. Global tuberculosis control report 2008. Available at http://www.who.
    int/mediacentre/factsheets/fs104/en/print.html. Accessed 15 Oct 2008.


45. Cobelens FG, van Deutekom H, Draayer-Jansen IE. Risk of infection withMycobacterium tuberculosis
    in travelers to areas of high tuberculosis endemicity. Lancet 2000; 356:461–465.


46. Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations,
    diagnosis, and outcome. Rev Infect Dis 1990; 12(4):583–590.


47. Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic
    abnormalities, and outcome in 109 treated adults. Am J Med 1990; 89(3):291–296.


48. Jindal SK, Aggarwal AN, Gupta D. Adult respiratory distress syndrome in the tropics. Clin Chest
    Med 2002; 23(2):445–455.


49. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Recomm Rep 2003;
    52(RR-11):1–77.


50. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of
    Mycobacterium tuberculosisin health-care facilities. MMWR Recomm Rep 1994; 43(RR-13):1–132.


51. Kritski AL, deJesus LS, Andrade MK, et al. Retreatment tuberculosis cases* factors associated with
    drug resistance and adverse outcomes. Chest 1997; 111(5):1162–1167.


52. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California, 1993–
    2006. Clin Infect Dis 2008; 47:450–457.


53. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance amongStreptococcus pneumonia
    isolated in the USA: update from PROTEKT US years 1–4. Ann Clin Microbiol Antimicrob 2008;
    7(1):1–11.


54. File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community
    acquired pneumonia. Chest 2004; 125(5):1888–901.


55. Surveillance for Travel-Associated Legionnaires Disease—United States 2005–2006. MMWR 2007;
    56(48):1261–1263.


56. Jernigan DB, Hofmann J, Cetron MS, et al. Outbreak of Legionnaires’ disease among cruise ship
    passengers exposed to a contaminated whirlpool spa. Lancet 1996; 347(9000):494–499.


57. Ruf B, Schu ̈rmann D, Horbach I, et al. Prevalence and diagnosis ofLegionella pneumonia: a 3-year
    prospective study with emphasis on application of urinary antigen detection. J Infect Dis 1990; 162(6):
    1341–1348.


58. Moser MR, Bender TR, Margolis HS, et al. An outbreak of influenza aboard a commercial airliner.
    Am J Epidemiol 1979; 110(1):1–6.


59. World Health Organization. Epidemic and pandemic alert response (EPR). Available at: http://
    http://www.who.int/csr/disease/influenza/vaccinerecommendations1/en/index1/html. Accessed 10 Oct
    2008.


60. CDC Health Alert. CDC recommends against the use of amantadine and rimantadine for the
    treatment or prophylaxis of influenza in the United States during the 2005–06 influenza season.
    Available at: http://www.cdc/gov/flu/han011406.htm. Accessed 16 Oct 2008.


61. World Health Organization. Haemorrhagic fever with renal syndrome: memorandum from a WHO
    meeting. Bull WHO 1983; 61(2):269–275.


62. Moolenaar RL, Dalton C, Lipman HB, et al. Clinical features that differentiate hantavirus pulmonary
    syndrome from three other acute respiratory illnesses. Clin Infect Dis 1995; 21(3):643–639.


63. Chapman LE, Ellis BA, Koster FT, et al. Discriminators between hantavirus-infected and -uninfected
    persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary
    syndrome. Clin Infect Dis 2002; 34(3):293–304.


64. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-
    controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.
    J Infect Dis 1991; 164(6):1119–1127.


65. Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, double-blind trial of intravenous
    ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect
    Dis 2004; 39(9):1307–1313.


66. White NJ. Melioidosis. Lancet 2003; 361(9370):1715–1722.


67. Sookpranee M, Boonma P, Susaengrat W, et al. Multicenter prospective randomized trial comparing
    ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and cotrimoxazole for
    treatment of severe melioidosis. Antimicrob Agents Chemother 1992; 36(1):158–162.


68. Dennis DT, Chow CC. Plague. Pediatr Infect Dis J 2004; 23(1):69–71.


69. Krishna G, Chitkara RK. Pneumonic plague. Semin Respir Infect 2003; 18(3):159–167.


70. Morgan J, Cano MV, Feikin DR, et al. A large outbreak of histoplasmosis among American travelers
    associated with a hotel in Acapulco, Mexico, spring 2001. Am J Trop Med Hyg 2003; 69(6):663–639.


71. Panackal AA, Hajjeh RA, Cetron MS, et al. Fungal infections among returning travelers. Clin Infect
    Dis 2002; 35(9):1088–1095.

Tropical Infections in Critical Care 337